title: Resveratrol inhibits human nasopharyngeal carcinoma cell growth via             blocking pAkt/p70S6K signaling pathways.
abstract: Resveratrol (trans-3,4',5-trihydroxystilbene) has been shown to exert potent             anticancer effects on various types of cancer through its anti-proliferative,             anti-angiogenic, antioxidant and pro-apoptotic functions. There is still a lack             of experimental evidence regarding whether resveratrol has potential anticancer             activity in human nasopharyngeal carcinoma (NPC) cells. The purpose of this study             was to explore the anticancer activity of resveratrol in human NPC cells both             in vitro and in vivo. Our results indicated that treatment with resveratrol led             to a time- and dose-dependent decrease in cell proliferation in NPC cells. A dose-dependent             increase in apoptosis in response to resveratrol treatment was also observed in             NPC cells. Flow cytometric analysis showed that treatment of NPC cells with resveratrol             led to cell cycle arrest at the S and G2/M phases. Mechanistically, resveratrol             treatment downregulated the expression of Bcl-2 and hypoxia-inducible factor-1α             (HIF-1α) proteins and upregulated the expression of caspase-3 protein. In addition,             resveratrol treatment also significantly decreased the phosphorylation levels             of Akt1, p70S6K and p-4E-BP-1 and the protein expression of several cyclins involved             in cell cycle regulation. In vivo studies further showed that resveratrol was             able to significantly inhibit the growth of NPC tumor xenografts in nude mice.             Collectively, our findings suggest that resveratrol exerts potent anti-prolife-rative             and pro-apoptotic effects on human NPC cells possibly through interfering with             the pAkt1/p70S6K signaling pathways, thus it may potentially be developed as an             effective agent for chemoprevention and chemotherapy of human NPC.
authors: Center for Gene Diagnosis, Zhongnan Hospital, Wuhan University, Wuhan, Hubei, PR China.
authors: Meihong
authors: M
authors: Zhang
authors: Xin
authors: X
authors: Zhou
authors: Keyuan
authors: K
authors: Zhou
mesh_terms: D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology* / Q000627:therapeutic use; D017209:Apoptosis / Q000187:drug effects; D002277:Carcinoma; D053148:Caspase 3 / Q000096:biosynthesis; D059447:Cell Cycle Checkpoints / Q000187:drug effects; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects*; D002470:Cell Survival; D016213:Cyclins / Q000378:metabolism; D005260:Female; D006801:Humans; D051795:Hypoxia-Inducible Factor 1, alpha Subunit / Q000096:biosynthesis; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D000077274:Nasopharyngeal Carcinoma; D009303:Nasopharyngeal Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D009368:Neoplasm Transplantation; D010766:Phosphorylation; D051057:Proto-Oncogene Proteins c-akt / Q000378:metabolism*; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000096:biosynthesis; D000077185:Resveratrol; D038762:Ribosomal Protein S6 Kinases, 70-kDa / Q000037:antagonists & inhibitors* / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects*; D013267:Stilbenes / Q000494:pharmacology* / Q000627:therapeutic use; D023041:Xenograft Model Antitumor Assays
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D016213:Cyclins; C497442:HIF1A protein, human; D051795:Hypoxia-Inducible Factor 1, alpha Subunit; D019253:Proto-Oncogene Proteins c-bcl-2; D013267:Stilbenes; D051057:Proto-Oncogene Proteins c-akt; D038762:Ribosomal Protein S6 Kinases, 70-kDa; D053148:Caspase 3; D000077185:Resveratrol